Our top pick for
AudioEye Inc is a software-application business based in the US. AudioEye shares (AEYE) are listed on the NASDAQ and all prices are listed in US Dollars. AudioEye employs 89 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$10.26|
|52-week range||$9.10 - $44.37|
|50-day moving average||$11.32|
|200-day moving average||$16.49|
|Wall St. target price||$22.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.85|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-0.48%|
|1 month (2021-09-20)||-0.68%|
|3 months (2021-07-22)||-29.77%|
|6 months (2021-04-22)||-56.47%|
|1 year (2020-10-21)||-40.45%|
|2 years (2019-10-21)||230.97%|
|3 years (2018-10-19)||28.25%|
|5 years (2016-10-20)||7,125.35%|
|Revenue TTM||$22.7 million|
|Gross profit TTM||$14.5 million|
|Return on assets TTM||-29.48%|
|Return on equity TTM||-76.4%|
|Market capitalisation||$120.3 million|
TTM: trailing 12 months
There are currently 321,582 AudioEye shares held short by investors – that's known as AudioEye's "short interest". This figure is 0.1% down from 321,907 last month.
There are a few different ways that this level of interest in shorting AudioEye shares can be evaluated.
AudioEye's "short interest ratio" (SIR) is the quantity of AudioEye shares currently shorted divided by the average quantity of AudioEye shares traded daily (recently around 82881.958762887). AudioEye's SIR currently stands at 3.88. In other words for every 100,000 AudioEye shares traded daily on the market, roughly 3880 shares are currently held short.
However AudioEye's short interest can also be evaluated against the total number of AudioEye shares, or, against the total number of tradable AudioEye shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AudioEye's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 AudioEye shares in existence, roughly 30 shares are currently held short) or 0.0643% of the tradable shares (for every 100,000 tradable AudioEye shares, roughly 64 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AudioEye.
Find out more about how you can short AudioEye stock.
We're not expecting AudioEye to pay a dividend over the next 12 months.
AudioEye's shares were split on a 1:25 basis on 7 August 2018. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AudioEye shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for AudioEye shares which in turn could have impacted AudioEye's share price.
Over the last 12 months, AudioEye's shares have ranged in value from as little as $9.1 up to $44.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AudioEye's is 2.182. This would suggest that AudioEye's shares are significantly more volatile than the average for this exchange and represent a higher risk.
AudioEye, Inc. provides software solutions to Internet, print, broadcast, and other media to people regardless of their network connection, device, location, or disabilities in the United States. The company provides patented Internet content publication and distribution software that enables conversion of media into accessible formats, as well as allows for real time distribution on various Internet connected devices. It offers AudioEye, an always-on testing, remediation, and monitoring solution that improves conformance with web content accessibility guidelines; identifies and fixes the common accessibility errors and addresses a range of disabilities including dyslexia, color blindness, epilepsy, and others; and provides additional solutions to provide for enhanced compliance and accessibility, including periodic manual auditing, manual remediations, and legal support services, as well as PDF remediation services and audit reports to help customers with their digital accessibility needs. The company serves small- and medium-sized businesses, corporate enterprises, non-profit organizations, and federal government agencies, as well as foreign, state, and local governments and agencies through content management system partners, platform and agency partners, authorized resellers, and the marketplace. AudioEye, Inc. was incorporated in 2005 and is based in Tucson, Arizona.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.